drugset / Trial / NCT03600025

Cellular Immune Responses in Typhoid Fever Patients and Vaccinees

NCT03600025

NaSingle-groupOpen-labelBasic science

Summary

Typhoid fever caused by Salmonella Typhi and Paratyphi causes over 21 million cases of febrile illness and 200,000 deaths are attributed to enteric fever each year. Typhoid fever is an enteric infection that results in febrile illness. Typhoid fever causes significant morbidity in the developing world especially young children.S. Typhi specific antibody responses are elicited in typhoid fever and following typhoid vaccination. Cross-reactive multifunctional CD+4 T cell mediated IL-17 responses have been shown in typhoid fever. As S. Typhi as an intracellular pathogen, cellular immune responses might be central to protection. S. Typhi peptide subunit vaccine elicits CD+4 T cell responses that correlate with protection in mice. The role of mucosal associated invariant T cell (MAIT) and natural killer (NK) cell responses in typhoid fever or following vaccination remain poorly understood. Transcriptome profiling of human immune responses to S. Typhi infection is not clearly understood. Establishing successful infection by S. Typhi evasion of T cell and neutrophil responses need to be investigated to better understand the correlates of protection.

Timeline

Start
2018-07-15
Primary completion
2021-09-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Typbar-TCV Vaccine 25 ug Intramuscular

Indications

No indication recorded.